Imunon, Inc. · NASDAQ:IMNN
Imunon — Investor Presentation (October 2026)
33 slides from Imunon's investor presentation, Oct 27, 2026
Slide 1: Imunon Investor Presentation
IMUNON Developing medicines harnessing the capability of DNA to power body’s immune system Investor Presentation Nasdaq: IMNN OCTOBER 2026
Slide 2: Safe Harbor Statement
Safe Harbor Statement DISCLOSURES For the purposes of this notice, the “presentation” that follows shall mean and include the slides that follow, the ral presentation ofthe slides by members of management of Imunon, Inc. (“IMUNON" or the “Company") or ‘any person on their behalf, any question-and-an
Slide 3: Offering Summary
Offering Summary ISSUER: EXCHANGE/SYMBOL: OFFERING TYPE: UPFRONT GROSS PROCEEDS: POTENTIAL MILESTONE WARRANT GROSS PROCEEDS: SECURITIES TO BE OFFERED: ANTICIPATED USE OF PROCEEDS: SOLE PLACEMENT AGENT: ANTICIPATED PRICING: SIMUNON Imunon, Inc. (“IMNN" or the “Company”) Nasdaq Capital Market: IMNN Be
Slide 4: Proposed Milestone Warrant Summary
SIMUNON Proposed Milestone Warrant Summary Expire on the earlier of (i) the five-year anniversary of the effective date of stockholder approval of the issuance of the shares upon exercise of the Tranche A, B, C, and D Common Warrants (the “Warrant Stockholder Approval”) or the date of issuance of su
Slide 5: Why Imunon: Investment Thesis
WHY IMUNON Investment Thesis Funding IMNN-001 IL-12 Registrational Study for 1st line Ovarian Cancer First-it clinically meaningful OS efficacy results in a randomized, well -Class Immunotherapy with favorable safety profile and controlled Phase 2 trial in newly diagnosed ovarian cancer population U
Slide 6: Great Unmet Need: High Recurrence, Low Survival
SIMUNON DISEASE BURDEN Great Unmet Need: Recurrence Rates are High and Survival Rates are Low Patient Outcomes and Frontline Standard of Care Unchanged for more than 25 years Epithelial ovarian cancer (EOC) is insidious and usually diagnosed at an advanced stage. Though EOC initially responds to tre
Slide 7: IL-12 Has Compelling Biology but Historical Delivery Limitations
11-12 BIOLOGY SIMUNON IL-12 Has Compelling Biology but Historical Delivery & Safety Limitations IL-12 activates both innate and adaptive immune systems in immunogenic tumors, but its development has been limited by delivery and safety challenges EOCis an immunogenic cancer where immu restore anti-tu
Slide 8: IMNN-001's Differentiated Approach to IL-12 Delivery
Si 'IMUNON DELIVERY PLATFORM on . F IMNN-001’s Differentiated Approach to IL-12 Delivery Local, durable, and safe IL-12 delivery at the tumor site with repeat dosing representing a key differentiating feature of IMNN-001's DNA-mediated approach IMNN-001 uses the Theraplas® platform for non-viral del
Slide 9: Biomarker Data Support Local Target Engagement and TME Remodeling
IMUNON BIOMARKERS Biomarker Data Support Local Target Engagement and TME Remodeling IMNN-001 increases IL-12 levels within the ascites without increasing systemic levels, helping shift the tumor microenvironment from immunologically “cold” to “hot” IMNN-001 achieves local increase in IL-12 in dose d
Slide 10: IMNN-001 Safely Targets the Micro-Environment of Ovarian Cancer
SIMUNON THE MECHANISM IMNN-001 Safely Targets the Micro-Environment of Ovarian Cancer Local production of safe and durable levels of a powerful anti-cancer immune agent, IL-12 Safe administration weekly, demonstrated in up to 17 doses over a 6-month period INTERLEUKIN 12 INDUCES STRONG ANTI-CANCER I
Slide 11: IMNN-001 Consistent Safety Profile
SAFETY SIMUNON IMNN-001 Consistent Safety Profile: OVATION-2, OVATION-3 and MRD Trial Safety IMNN-001 Continues to Allow Safe and Tolerable Repeated Delivery of Tumor-Localized IL-12 OVATION 2, PHASE 2 - KEY SAFETY OBSERVATIONS: + None of the systemic dose-limiting toxicities associated with IV reco
Slide 12: Investment Case: Potential Breakthrough in Ovarian Cancer
INVESTMENT CASE IMNN-001: A Potential Breakthrough in Newly Diagnosed Ovarian Cancer 02 03 04 No other frontline ovarian cancer trial has shown an OS improvement; IMNN-001 has a favorable benefit/risk profile Large randomized Phase 2 OVATION-2: 14.7-month OS improvement by IMNN-001 over standard of
Slide 13: OVATION-2 Overall Survival Improvement
OVATION-2 - PHASE 2 ITT Population OVATION 2 Data Show Continued IMNN-001 Overall Survival Improvement aT Median OS: 45.1 mo IMNN+NACT, 30.4 mo NACT Difference, 95% Cl: 14.75 (-3.8, 33.3), one-sided p-value = 0.06 084 Modified Weighted Log Rank, one-sided p-value = 0.058 = 06-4 = z od 6 +4 a | 024 —
Slide 14: OVATION-2 PARPi Maintenance Subgroup
SIMUNON OVATION-2 » PARPI MAINTENANCE SUBGROUP OVATION 2 PARPi-Treated Show 24-month IMNN-001 Overall Survival Improvement rr c ox 4 £ v6 2 + % os } Median OS: 65.6 mo IMNN+NACT, 41.4 mo NACT, bes = Difference 24.2 mo* o24 Modified Weighted Log Rank, one-sided p-value = 0.186 —+— IMNN-001 + NACT NAC
Slide 15: Phase 2 Study Showcased at ASCO
SIMUNON Our Phase 3 Clinical Research is of Great Importance to the Medical Community Our Landmark Phase 2 Study was Showcased at ASCO with a Platform Presentation 2025 ASCO. ANNUAL MEETING G Cc A Phase I/II study of the Safety and Efficacy of IP Y IMNN-001 in combination with N/ACT in patients newl
Slide 16: Evidence Summary
“IMUNON EVIDENCE SUMMARY Consistent treatment effects favoring IMNN-001 across all Phase 2 efficacy endpoints, favorable safety, and biomarker validation suggests potential for reproducibility in phase 3 Phase 2 Clinical Endpoints associated with Overall Survival TREATMENT EFFECT CONSISTENTLY FAVORS
Slide 17: MRD Translational Study: Deep Responses and Immune Remodeling
SIMUNON MD ANDERSON TRANSLATIONAL STUDY MRD Translational Study: Deep Responses and Immune Remodeling in the IMNN-001 Arm IMNN-001 Shows Lower MRD-Positive Rate, Higher ctDNA Clearance, and Longer Recurrence-Free Survival TREATMENT COURSE & OUTCOME BY PATIENT (ITT COHORT) RECURRENCE-FREE SURVIVAL: M
Slide 18: OVATION-3 Designed to Confirm the OS Effect
SIMUNON PHASE 3 DESIGN OVATION-3 Is Designed to Prospectively Confirm the OS Effect OVATION-3 is an ongoing randomized, controlled Phase 3 trial evaluating IMNN-001 in women with newly diagnosed advanced ovarian cancer eligible for neoadjuvant chemotherapy FRONTLINE THERAPY MAINTENANCE THERAPY SoC+I
Slide 19: Upcoming Catalysts
UPCOMING CATALYSTS. SJ Key Anticipated Near-Term Milestones for OVATION-3 & IMNN-001 IMUNON Enrollment progress, scientific presentations, and data readouts supporting the registrational pathway apes OVATION-3 iDMC Review ae Independent Data Monitoring Committee assessment of safety and trial progre
Slide 20: Pipeline: IMNN-001 Indications
PIPELINE IMNN-001 Current and Potential Future Indications Theraplas Platform Capable of a Pipeline of DNA-Based Transformative Medicines PLATFORM DELIVERY. PROGRAM INDICATIONS) biscovery IND ENABLING PHASE 1 PHASE 2 SIMUNON PHASE 2 IL-12 (OVATION 3) 1L-12 in combination with Avastin® IL-12 (OVATION
Slide 21: IMNN-001 Combinatorial Strategies
SIMUNON COMBINATION STRATEGY IMNN-001’s Potential for Combinatorial Strategies IMNN-001 is evaluated in combination with established ovarian cancer therapies, and its ability to create an immunostimulatory TME provides rationale for combinations with emerging modalities COMBINATIONS IN CLINICAL EVAL
Slide 22: Imunon in Phase 3, Potential for Early Stopping
EXECUTION IMUNON IMUNON in Phase 3, Well Positioned with Potential for Early Stopping Executing against the plan Robust Data from 112 patient OVATION-2 (Phase 2) demonstrating IMNN-001 improvement over SoC + Confidence in Phase 3 trial based on consistency of clinical data across all endpoints and s
Slide 23: Contact Us
SIMUNON CONTACT US Corporate Information Research Facility Huntsville, AL Headquarters Lawrenceville, NJ IMUNON Contact ONLINE 997 Lenox Drive P: 609-896-9100 www.imunon.com F: 609-896-2200 Nasdaq: IMNN Suite 100 Lawrenceville, NJ 08648
Slide 24: Appendix
Appendix Slides for use in discussion as back-up SimuNon | ie | Se
Slide 25: IL-12 and its Effector IFN-y: Drivers of Antitumor Immunity
IL-12 and its Effector IFN-y: Critical Drivers of Antitumor Immunity Harnessing Both Innate and Acquired Immunity Acquired Immunity * Tlymphocytes * Blymphocytes Innate Immunity * Monocytes * Macrophages * Dendritic Cells * Neutrophils * NKcells = Rees ee Pe / |) Batrogens through Tok tks or other r
Slide 26: IFN-y Effects in Cancer are Multifactorial and Powerful
IFN-y Effects in Cancer are Multifactorial and Powerful Not Just Immune-Related but Also Affecting Pathways Regulating Cancer Progression, Angiogenesis and Apoptosis <=> ‘Tumor senescence metastasis. TAR/STAT TCasPTT.BF 4SUC7ALL Tumor dormancy a y % .@ ‘Treg fragility Cancer cell apoptosis number of
Slide 27: OVATION-3 Trial Catalyst Timeline
OVATION-3 Trial Catalyst OVATION-3 Phase 3 Planned Timeline Expected Patient Enrollment Formal Interim Analysis, Final Study Readout Primary Endpoint 50% enrolled - Q1 2028 total events (n=245), IA#1, 60% of events (n = 147), estimated Q2 2031 100% enrolled - Q1 2029 estimated Q1 2030 1A#2, 80% of e
Slide 28: Phase 3 Amendment Drivers
PHASE 3 Amendment Drivers OVATION 2 Data Show Continued IMNN-001 Overall Survival Improvement Protocol Amendment submitted to FDA to strengthen Design and Analysis plan Protocol Amendment motivated by: * FDA OS in Oncology Clinical Trials Guidance * Discussion of 2-stage analysis strategies * Magnit
Slide 29: Phase 3 Amendment Value
PHASE 3 Amendment Value OVATION-3 Amendment: Strategic Protocol Refinements with goal to Maximize Development Value Design and analysis plan modifications submitted & under review with FDA What Changed and Why: Statistical Approach: Now with a primary statistical strategy and optional model. + Align
Slide 30: Amendment Catalyst Timing
PHASE 3 Ca lyst Timing Amendment Plans for IA and Full Trial Readout Earlier than Current Protocol Trial focus on entire Neoadjuvant-eligible Newly Diagnosed OC Population. No need to sequence HRD+ before ITT population Current Protocol Designed with a sub-set population as initial readout focus (HR
Slide 31: Phase 3 Amendment Goals
PHASE 3 Amendment Goals OVATION 3 Amendment Goals: Aim to Maximize the Probability of Trial Success Primary Endpoint focused on 500 All-Comer’s population, 245 targeted OS events for full trial Amendment leverages and aims to align with FDA’s recent draft guidance on the assessment of overall surviv
Slide 32: FDA Analysis Strategy Guidance
FDA Analysis Strategy Guidance Timely FDA OS Guidance Motivates OV-3 Amendment to Maximize Study Power Approaches to Assessment of Overall Survival in Oncology Clinical Trials Guidance for Industry DRAFT GUIDANCE “Th etane dosnt ing eh fr oman pare as palconon in be Feral Reger ft ce amc avai ofthe
Slide 33: Applying FDA Guidance: Weighted Log-Rank for Overall Survival
Applying FDA Guidance Weighted Log-Rank for Overall Survival Emphasizing Clinically Meaningful Portion of the Survival Distribution Why Weighted Log-Rank? The Potential Clinical Advantage Standard Log-Rank Focus on the Middle of the Distribution Se ue Ce Grane Beets CSE LETS For fatal diseases, the